CABLIVI (caplacizumab-yhdp) is a recombinant, monoclonal antibody fragment that specifically targets von Willebrand factor (vWF). This targeted mechanism helps prevent the formation of microthrombi in the microcirculation by inhibiting the interaction between vWF and platelets, which is central to the pathogenesis of acquired thrombotic thrombocytopenic purpura (aTTP). As part of the treatment regimen for aTTP, CABLIVI is used in combination with plasma exchange and immunosuppressive therapy. This combination provides a multifaceted approach to reduce the burden of thrombotic events, control platelet consumption, and mitigate organ damage, ultimately improving patient outcomes.

Administered through intravenous and subcutaneous routes, CABLIVI provides flexibility in treatment delivery. The recommended dosage schedule involves an initial bolus intravenous injection, followed by subcutaneous injections during the plasma exchange phase. Treatment continues for up to 30 days post-plasma exchange, with adjustments based on disease activity. Notably, CABLIVI has demonstrated efficacy in reducing aTTP relapse and improving recovery, although treatment may be extended in certain cases with persistent symptoms.